Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.01
+7.4%		$0.00
$0.00
▼
$27,092.88
$6K1.21102.19 million shs10.07 million shs
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
$0.00
$0.00
$0.00
▼
$0.02
$4K2.476,517 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
+7.35%+7.35%+160.71%-88.24%-100.00%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
0.00%+166.67%+300.00%+300.00%+300.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$0.01
+7.4%		$0.00
$0.00
▼
$27,092.88
$6K1.21102.19 million shs10.07 million shs
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
$0.00
$0.00
$0.00
▼
$0.02
$4K2.476,517 shsN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
▼
$0.00
$6K1.6183,499 shsN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
+7.35%+7.35%+160.71%-88.24%-100.00%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
0.00%+166.67%+300.00%+300.00%+300.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%0.00%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aditxt, Inc. stock logo
ADTX
Aditxt
1.00
SellN/AN/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EFTR, NAVB, ADTX, and GNCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Aditxt, Inc. stock logo
ADTX
Aditxt
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aditxt, Inc. stock logo
ADTX
Aditxt
$14.34K0.42N/AN/A$259.70 per share0.00
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
N/AN/AN/AN/A($1.94) per shareN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aditxt, Inc. stock logo
ADTX
Aditxt
-$41.71M-$100,788.35N/AN/AN/A-360,152.50%-374.60%-105.93%N/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
-$35.81M-$13.08N/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.06
0.05
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
57.67%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%

Insider Ownership

CompanyInsider Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
0.01%
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
4.70%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aditxt, Inc. stock logo
ADTX
Aditxt
60816,000816,000No Data
eFFECTOR Therapeutics, Inc. stock logo
EFTR
eFFECTOR Therapeutics
104.70 million4.48 millionNo Data
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data

Recent News About These Companies

Navidea Biopharmaceuticals Files for Chapter 11 Bankruptcy
October 9, 2025  |  contractpharma.comC
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
October 8, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251008843839/en/navidea-biopharmaceuticals-inc.-files-for-bankruptcy/
AIG rejects D&O claim as Navidea directors sue over legal bills
September 2, 2025  |  insurancebusinessmag.comI
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
May 21, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250520421964/en/navidea-biopharmaceuticals-inc.-announces-extension-of-authority-to-implement-a-reverse-stock-split/
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
March 31, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250331822538/en/navidea-biopharmaceuticals-announces-the-extension-of-plan-designed-to-protect-nols-and-other-tax-assets/
Navidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market Trades
December 23, 2024  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/navb/pre-market-trades
Navidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News Summary
October 28, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NAVB
Navidea Biopharmaceuticals gets grant for treatment of flaviviridae family virus infections
August 22, 2024  |  pharmaceutical-technology.comP
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
July 3, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240703199069/en/navidea-biopharmaceuticals-inc.-announces-results-of-exploratory-analysis-completed-on-july-2-2024/
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
June 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240620380826/en/navidea-biopharmaceuticals-inc.-announces-special-meeting-of-stockholders-to-be-held-july-8-2024/
SK Biopharmaceuticals Co. Ltd.
May 25, 2024  |  wsj.comhttps://www.wsj.com/market-data/quotes/KR/326030/financials
Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
May 3, 2024  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/dawn
Navidea Biopharmaceuticals files patent for polymeric compound for treating diseases involving macrophages
March 6, 2024  |  pharmaceutical-technology.comP
Navidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextran
March 5, 2024  |  pharmaceutical-technology.comP
Central Ohio public company voluntarily deregisters stock
January 29, 2024  |  bizjournals.comhttps://www.bizjournals.com/columbus/news/2024/01/29/navidea-sec-stock-deregister.html
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
January 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/navidea-biopharmaceuticals-inc-files-form-000500004.html?.tsrc=rss
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
January 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/navidea-biopharmaceuticals-inc-files-form-000500004.html?.tsrc=rss
Suzhou Zelgen Biopharmaceuticals Co Ltd (688266)
January 11, 2024  |  investing.comhttps://www.investing.com/equities/suzhou-zelgen-biopharmaceuticals-historical-data
Navidea settles litigation with Capital Royalty, stock rallies 30%
December 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/navidea-settles-litigation-with-capital-royalty-stock-rallies-30/ar-AA1kR3hj
Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation
December 1, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/navidea-biopharmaceuticals-crg-settle-all-ongoing-litigation-1032866326

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aditxt stock logo

Aditxt NASDAQ:ADTX

$0.0073 +0.00 (+7.35%)
As of 09/4/2026 03:59 PM Eastern

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

eFFECTOR Therapeutics stock logo

eFFECTOR Therapeutics NASDAQ:EFTR

$0.0008 0.00 (0.00%)
As of 09/3/2026

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas